BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37197957)

  • 1. Anti-melanoma Differentiation-associated Gene 5 Antibody-positive Dermatomyositis Presenting as Refractory Gingivitis at the First Clinical Manifestation.
    Kawakami E; Uchida T; Iwamoto N; Hara K; Egashira K; Kawakami A
    Intern Med; 2024 Jan; 63(1):131-134. PubMed ID: 37197957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case of autoimmune pulmonary alveolar proteinosis during the course of treatment of rapidly progressive interstitial pneumonia associated with anti-MDA5 antibody-positive dermatomyositis.
    Yatomi M; Akasaka K; Sato S; Chida M; Kanbe M; Sawada H; Yokota I; Wakamatsu I; Muto S; Sato M; Yamaguchi K; Miura Y; Tsurumaki H; Sakurai R; Hara K; Koga Y; Sunaga N; Yamakawa H; Matsushima H; Yamazaki S; Endo Y; Motegi SI; Hisada T; Maeno T
    BMC Pulm Med; 2024 Apr; 24(1):170. PubMed ID: 38589870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Three cases report of juvenile dermatomyositis with positive anti-melanoma differentiation associated gene 5 (MDA5) antibody and severe interstitial lung disease and literature review].
    Hou J; Zhou ZX; Li JG; Xu YJ; Ding YC
    Zhonghua Er Ke Za Zhi; 2019 Dec; 57(12):928-933. PubMed ID: 31795559
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-MDA5 and anti-SSA/Ro52 antibodies double-positive dermatomyositis overlapping with rheumatoid arthritis-associated interstitial lung disease: A case report.
    Xiong H; Tan Q; Luo F; Yuan X; Ma W; Yao X
    Int J Rheum Dis; 2022 Dec; 25(12):1437-1440. PubMed ID: 36029141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-MDA5 Antibody-positive Dermatomyositis with Rapidly Progressive Interstitial Pneumonia Presenting with Nephrotic Syndrome during Treatment with Corticosteroids and Cyclosporine.
    Kawamoto S; Abe T; Nagahori K; Yoshino A; Fujii A; Ono Y; Ueda Y; Takeda T
    Intern Med; 2022 Jul; 61(13):2007-2012. PubMed ID: 34776485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review.
    Huang K; Vinik O; Shojania K; Yeung J; Shupak R; Nimmo M; Avina-Zubieta JA
    Rheumatol Int; 2019 Nov; 39(11):1971-1981. PubMed ID: 31375890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis.
    So H; Wong VTL; Lao VWN; Pang HT; Yip RML
    Clin Rheumatol; 2018 Jul; 37(7):1983-1989. PubMed ID: 29713969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A fatal interstitial lung disease in an anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody negative patient with juvenile dermatomyositis.
    Yeşilbaş O; Yıldız M; Yozgat CY; Tahaoğlu I; Yazan H; Çakır E; Adrovic A; Şahin S; Barut K; Kasapçopur Ö
    Turk J Pediatr; 2021; 63(5):903-908. PubMed ID: 34738372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrence of anti-MDA5 antibody-positive clinically amyopathic dermatomyositis after long-term remission: A case report.
    Endo Y; Koga T; Ishida M; Fujita Y; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Umeda M; Fukui S; Nishino A; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Kuwana M; Hosono Y; Mimori T; Kawakami A
    Medicine (Baltimore); 2018 Jun; 97(26):e11024. PubMed ID: 29952940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease: report of two cases.
    Mehta AA; Paul T; Cb M; Haridas N
    BMJ Case Rep; 2021 Apr; 14(4):. PubMed ID: 33910791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy.
    Ge Y; Li S; Tian X; He L; Lu X; Wang G
    Clin Rheumatol; 2021 Jun; 40(6):2311-2317. PubMed ID: 33411136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-MDA5 antibody-positive hypomyopathic dermatomyositis complicated with pneumomediastinum.
    Yashiro M; Asano T; Sato S; Kobayashi H; Watanabe H; Miyata M; Migita K
    Fukushima J Med Sci; 2018; 64(2):89-94. PubMed ID: 30158335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease.
    Yoshida N; Okamoto M; Kaieda S; Fujimoto K; Ebata T; Tajiri M; Nakamura M; Tominaga M; Wakasugi D; Kawayama T; Kuwana M; Mimori T; Ida H; Hoshino T
    Respir Investig; 2017 Jan; 55(1):24-32. PubMed ID: 28012490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease.
    Motegi SI; Sekiguchi A; Toki S; Kishi C; Endo Y; Yasuda M; Ikeuchi H; Sakairi T; Hara K; Yamaguchi K; Maeno T; Hiromura K; Ishikawa O
    Eur J Dermatol; 2019 Oct; 29(5):511-517. PubMed ID: 31617496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis.
    Sakamoto N; Ishimoto H; Nakashima S; Yura H; Miyamura T; Okuno D; Hara A; Kitazaki T; Kakugawa T; Ishimatsu Y; Satoh M; Mukae H
    Intern Med; 2019 Mar; 58(6):837-841. PubMed ID: 30449789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis.
    Sakamoto S; Okamoto M; Kaieda S; Fujimoto K; Nagata S; Tominaga M; Nakamura M; Zaizen Y; Nouno T; Koga T; Kawayama T; Kuwana M; Ida H; Hoshino T
    Respir Investig; 2018 Nov; 56(6):464-472. PubMed ID: 30150008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment.
    Koichi Y; Aya Y; Megumi U; Shunichi K; Masafumi S; Hiroaki M; Masahiko K; Shinsuke K; Manabu U; Kenichiro H; Fumiaki A; Nozomi A; Toshitaka M; Masayoshi Y; Chikako K; Yoshinao M; Tatsuo S; Masahiko K
    Mod Rheumatol; 2017 May; 27(3):536-540. PubMed ID: 25698373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review.
    Nishi K; Ogura M; Tamai N; Gima M; Ide K; Koinuma G; Kamei K; Ito S
    Pediatr Rheumatol Online J; 2022 Aug; 20(1):60. PubMed ID: 35927666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-MDA5 antibody-associated clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease.
    Horino T; Inotani S; Nakajima K; Ohnishi H; Komori M; Terada Y
    Joint Bone Spine; 2022 Nov; 89(6):105456. PubMed ID: 36108903
    [No Abstract]   [Full Text] [Related]  

  • 20. Spontaneous pneumomediastinum in a dermatomyositis patient with anti-melanoma differentiation-associated gene-5 antibody and interstitial lung disease despite an initial response to immunosuppressant.
    Chan CWS; Chung HY; Lau CS; Tsang HHL
    Int J Rheum Dis; 2019 Mar; 22(3):521-524. PubMed ID: 28580698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.